Essen. A new position created to boost research and development in Evonik’s Baby Care Business Line has been filled with a proven industry expert from the company’s own ranks. Dr. Scott Smith, who took over as research fellow at Baby Care on April 1, 2016, will contribute his know-how to all technological and product innovations, coordinating the work of research, application technology, and sales for all R&D projects of the Business Line.
Smith, who holds a doctorate in chemistry, has close to thirty years of research experience in the field of superabsorbents, both in the U.S. and in Germany. He has played a role in the development of more than fifty patents in this area. As research fellow, Smith works for the Innovation Management unit of Baby Care, and is based in Krefeld.
"Based on his many years of involvement in research, Dr. Smith has in-depth knowledge of this industry’s requirements. In his new position, he will make his knowledge and contacts available to all internal and external stakeholders," explained Norbert Westerholt, head of Evonik’s Baby Care Business Line, about the function of the new position.
As the globally leading manufacturer of superabsorbents for the hygiene industry, Evonik aims to underscore and further strengthen its position by boosting its proximity to customers and targeted product innovation to differentiate itself from the competition.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around
€4.9 billion in 2015.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.